$RTTR Ritter Pharmaceuticals Inc. | Nasdaq


Ritter Pharmaceuticals Inc develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon thereby effectively adapting the gut microbiome to assist in digesting lactose that reaches the large intestine.